282 related articles for article (PubMed ID: 26889976)
1. A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma.
Kao SC; Kirschner MB; Cooper WA; Tran T; Burgers S; Wright C; Korse T; van den Broek D; Edelman J; Vallely M; McCaughan B; Pavlakis N; Clarke S; Molloy MP; van Zandwijk N; Reid G
Br J Cancer; 2016 Mar; 114(5):524-31. PubMed ID: 26889976
[TBL] [Abstract][Full Text] [Related]
2. High tumor cell platelet-derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma.
Ollila H; Paajanen J; Wolff H; Ilonen I; Sutinen E; Välimäki K; Östman A; Anttila S; Kettunen E; Räsänen J; Kallioniemi O; Myllärniemi M; Mäyränpää MI; Pellinen T
J Pathol Clin Res; 2021 Sep; 7(5):482-494. PubMed ID: 33955203
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
Laszlo V; Hoda MA; Garay T; Pirker C; Ghanim B; Klikovits T; Dong YW; Rozsas A; Kenessey I; Szirtes I; Grusch M; Jakopovic M; Samarzija M; Brcic L; Kern I; Rozman A; Popper H; Zöchbauer-Müller S; Heller G; Altenberger C; Ziegler B; Klepetko W; Berger W; Dome B; Hegedus B
J Pathol; 2015 Oct; 237(2):203-14. PubMed ID: 26011651
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia.
Alì G; Borrelli N; Riccardo G; Proietti A; Pelliccioni S; Niccoli C; Boldrini L; Lucchi M; Mussi A; Fontanini G
J Thorac Oncol; 2013 Nov; 8(11):1389-95. PubMed ID: 24084442
[TBL] [Abstract][Full Text] [Related]
5. CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome.
Ortolan E; Giacomino A; Martinetto F; Morone S; Lo Buono N; Ferrero E; Scagliotti G; Novello S; Orecchia S; Ruffini E; Rapa I; Righi L; Volante M; Funaro A
Oncotarget; 2014 Aug; 5(15):6191-205. PubMed ID: 25026285
[TBL] [Abstract][Full Text] [Related]
6. Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.
Kirschner MB; Pulford E; Hoda MA; Rozsas A; Griggs K; Cheng YY; Edelman JJ; Kao SC; Hyland R; Dong Y; László V; Klikovits T; Vallely MP; Grusch M; Hegedus B; Dome B; Klepetko W; van Zandwijk N; Klebe S; Reid G
Br J Cancer; 2015 Sep; 113(6):963-9. PubMed ID: 26263483
[TBL] [Abstract][Full Text] [Related]
7. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
[TBL] [Abstract][Full Text] [Related]
8. CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness.
Inaguma S; Lasota J; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Schrump DS; Hassan R; Kasai K; Miettinen M; Ikeda H
J Pathol; 2020 Feb; 250(2):205-216. PubMed ID: 31639216
[TBL] [Abstract][Full Text] [Related]
9. Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study.
Hoda MA; Dong Y; Rozsas A; Klikovits T; Laszlo V; Ghanim B; Stockhammer P; Ozsvar J; Jakopovic M; Samarzija M; Brcic L; Bendek M; Szirtes I; Reid G; Kirschner MB; Kao SC; Opitz I; Weder W; Frauenfelder T; Nguyen-Kim TD; Aigner C; Klepetko W; van Zandwijk N; Berger W; Dome B; Grusch M; Hegedus B
Eur J Cancer; 2016 Aug; 63():64-73. PubMed ID: 27288871
[TBL] [Abstract][Full Text] [Related]
10. Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.
Kadota K; Villena-Vargas J; Nitadori J; Sima CS; Jones DR; Travis WD; Adusumilli PS
Ann Surg Oncol; 2015 Sep; 22(9):3136-43. PubMed ID: 25608772
[TBL] [Abstract][Full Text] [Related]
11. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.
Reid G; Pel ME; Kirschner MB; Cheng YY; Mugridge N; Weiss J; Williams M; Wright C; Edelman JJ; Vallely MP; McCaughan BC; Klebe S; Brahmbhatt H; MacDiarmid JA; van Zandwijk N
Ann Oncol; 2013 Dec; 24(12):3128-35. PubMed ID: 24148817
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.
Battolla E; Canessa PA; Ferro P; Franceschini MC; Fontana V; Dessanti P; Pinelli V; Morabito A; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2017 Mar; 37(3):1387-1391. PubMed ID: 28314308
[TBL] [Abstract][Full Text] [Related]
13. Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
Kao SC; Cheng YY; Williams M; Kirschner MB; Madore J; Lum T; Sarun KH; Linton A; McCaughan B; Klebe S; van Zandwijk N; Scolyer RA; Boyer MJ; Cooper WA; Reid G
J Thorac Oncol; 2017 Sep; 12(9):1421-1433. PubMed ID: 28629895
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and Prognostic Performance of Secreted Protein Acidic and Rich in Cysteine (SPARC) Assay for Detecting Primary and Recurrent Urinary Bladder Cancer.
Critselis E; Rava M; Marquez M; Lygirou V; Chatzicharalambous D; Liapi P; Lichtinghagen R; Brand K; Cecchini L; Vlahou A; Malats N; Zoidakis J
Proteomics Clin Appl; 2019 Mar; 13(2):e1800148. PubMed ID: 30632279
[TBL] [Abstract][Full Text] [Related]
15. Tumor/stromal caveolin-1 expression patterns in pleural mesothelioma define a subgroup of the epithelial histotype with poorer prognosis.
Righi L; Cavallo MC; Gatti G; Monica V; Rapa I; Busso S; Albera C; Volante M; Scagliotti GV; Papotti M
Am J Clin Pathol; 2014 Jun; 141(6):816-27. PubMed ID: 24838326
[TBL] [Abstract][Full Text] [Related]
16. M14K and M38K malignant pleural mesothelioma cell lines preserve the same claudin-based phenotype in vivo.
Chaouche-Mazouni S; Copin MC; Lassalle P; Lebaili N; Cortot A; Scherpereel A
In Vivo; 2013; 27(2):227-32. PubMed ID: 23422483
[TBL] [Abstract][Full Text] [Related]
17. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.
Creaney J; Dick IM; Meniawy TM; Leong SL; Leon JS; Demelker Y; Segal A; Musk AW; Lee YC; Skates SJ; Nowak AK; Robinson BW
Thorax; 2014 Oct; 69(10):895-902. PubMed ID: 25037982
[TBL] [Abstract][Full Text] [Related]
18. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
Villanova T; Gesmundo I; Audrito V; Vitale N; Silvagno F; Musuraca C; Righi L; Libener R; Riganti C; Bironzo P; Deaglio S; Papotti M; Cai R; Sha W; Ghigo E; Schally AV; Granata R
Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2226-2231. PubMed ID: 30659154
[TBL] [Abstract][Full Text] [Related]
19. Mdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma.
Mairinger FD; Walter RF; Ting S; Vollbrecht C; Kollmeier J; Griff S; Hager T; Mairinger T; Christoph DC; Theegarten D; Schmid KW; Wohlschlaeger J
Future Oncol; 2014 May; 10(6):995-1005. PubMed ID: 24941985
[TBL] [Abstract][Full Text] [Related]
20. Comparison of SKIP expression in malignant pleural mesotheliomas with Ki-67 proliferation index and prognostic parameters.
Türkcü G; AlabalIk U; Keles AN; Ibiloglu I; Küçüköner M; Sen HS; Büyükbayram H
Pol J Pathol; 2016 Jun; 67(2):108-13. PubMed ID: 27543864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
